Radionuclide therapy effective in high-grade neuroendocrine neoplasms


  • Dawn O'Shea
  • Univadis Medical News
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

Peptide receptor radionuclide therapy (PRRT) is safe and effective for patients with grade 3 (G3) neuroendocrine neoplasms (NENs), according to research presented at the Society of Nuclear Medicine and Molecular Imaging's (SNMMI) annual meeting.

In the study, 69 patients with grade 3 (G3) neuroendocrine neoplasms (NENs) with a Ki-67 proliferation index of >20%, received PRRT with 177lutetium (177Lu) and/or 90Y-labelled DOTATATE or DOTATOC.

Forty-six patients had pancreatic NENs, 11 had unknown primary cancer, six had midgut NENs, three had gastric NENs, and three had rectal NENs.

PRRT was applied as first-line treatment in eight patients (11.6%), as second-line treatment in 25 patients (36.2%), and as third-line therapy in 28 patients (40.6%). The time span (mean ± SD) between biopsy for the assessment of Ki-67 and the first treatment cycle was 27.1 ± 36.8 months. Median follow-up was 94.3 months.

Median progression-free survival (PFS) and overall survival (OS) were 9.6 months and 19.9 months, respectively. For G3 NEN with Ki-67 ≤55% (n=53), median PFS was 11 months and median OS 22 months. Patients with Ki-67 >55% (n=11), had median PFS and OS of four months and seven months, respectively.

PRRT was well-tolerated, with no hepatotoxicity or grade 3/4 haematotoxicity, and no significant decline in renal function.